STOCK TITAN
  1. Home
  2. News
  3. TEVA

Teva Pharmaceutical Industries Limited American Depositary Shares - TEVA STOCK NEWS

Welcome to our dedicated page for Teva Pharmaceutical Industries American Depositary Shares news (Ticker: TEVA), a resource for investors and traders seeking the latest updates and insights on Teva Pharmaceutical Industries American Depositary Shares stock.

Teva Pharmaceutical Industries Limited (NASDAQ: TEVA) is a leading Israeli multinational pharmaceutical company headquartered in Tel Aviv, Israel. As the world's largest generic drug manufacturer, Teva plays a pivotal role in the global healthcare industry. The company derives approximately 50% of its sales from North America, contributing significantly to the total number of generic prescriptions in the United States.

Teva's extensive portfolio includes not only generic drugs but also active pharmaceutical ingredients (APIs) and proprietary pharmaceuticals. The company's operations are categorized into three main therapeutic areas:

  • Central Nervous System (CNS): Featuring notable products such as Copaxone, Ajovy, and Austedo, Teva addresses critical CNS disorders with innovative treatments.
  • Respiratory: Products like Qvar and ProAir contribute to Teva's robust respiratory medicine lineup, catering to patients with various respiratory conditions.
  • Oncology: Teva's oncology portfolio includes groundbreaking medicines such as Truxima, Herzuma, and Bendeka/Treanda, providing essential treatments for cancer patients.

In addition to its pharmaceutical products, Teva is a major player in active pharmaceutical ingredients, offering contract manufacturing services and owning Anda, a U.S.-based distributor of generic and specialty drugs.

Teva's global presence extends beyond North America, with significant operations in Europe, Japan, Russia, and its home country, Israel. The company's strategic partnerships and innovations keep it at the forefront of the pharmaceutical industry. Recent developments include advancements in biosimilars and innovative treatments.

Financially, Teva continues to maintain a strong position, focusing on growth and resilience amidst market challenges. The company is committed to improving patient health worldwide by providing high-quality, affordable medicines.

News

Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results and 2024 Financial Guidance at 8 a.m. ET on January 31, 2024

Rhea-AI Summary
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) will release its fourth quarter and full year 2023 financial results and financial guidance for 2024 on January 31, 2024. A conference call and live webcast will follow the release at 8:00 a.m. ET. Participants can register in advance for the call and access the webcast on Teva's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.62%
Tags
conferences earnings
-
News

Teva to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announces CEO's participation in the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.29%
Tags
conferences
-
News

Teva and Biolojic Design Announce Exclusive License Agreement for the Development of a Therapeutic Antibody for Atopic Dermatitis and Asthma

Rhea-AI Summary
Teva Pharmaceutical Industries Ltd. (TEVA) and Biolojic Design Ltd. announced an exclusive license agreement to develop a potential novel antibody-based therapy for the treatment of Atopic Dermatitis and Asthma. BD9, a dual specific antibody, has the potential to target IL-13 / TSLP and treat inflammatory diseases such as atopic dermatitis and asthma. This collaboration supports Teva's Pivot to Growth strategy and aims to enhance the company's early-stage pipeline through strategic partnerships.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.79%
Tags
none
News

New Post Hoc Phase 3 Data Analysis Shows AJOVY® (fremanezumab) Reduced Migraine Attacks in Adults with Migraine and Co-morbid Obesity

Rhea-AI Summary
Teva Pharmaceutical Industries Ltd. (TEVA) reports that a post hoc analysis of two phase 3 clinical studies presented at the European Headache Congress has shown the effectiveness of the migraine prevention treatment AJOVY® (fremanezumab) in reducing migraine attacks in patients with migraine and co-morbid obesity. The analysis compared the safety and efficacy of fremanezumab migraine preventive treatment in obese migraine patients vs normal weight migraine patients for a period of 6 months. After 6 months of treatment, monthly migraine days in migraine patients with high BMI was reduced to 6.8 vs 7.2 for normal weight patients. Adverse events in patients with obesity were similar to non-obese patients treated with fremanezumab.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.29%
Tags
clinical trial
-
News

Teva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease Treatment

Rhea-AI Summary
Teva Pharmaceuticals (TEVA) closes collaboration deal with Sanofi (SAN, SNY) to co-develop and co-commercialize asset TEV '574, currently in Phase 2b clinical trials for ulcerative colitis and Crohn's disease. Teva to receive $500 million upfront payment and up to $1 billion in milestones. Joint development and profit sharing agreement with Sanofi. Estimated 10 million people worldwide live with IBD.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.34%
Tags
none
-
News

Teva to Present at the 6th Annual Evercore ISI HealthCONx Conference

Rhea-AI Summary
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) to present at Evercore ISI HealthCONx Conference on November 28, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.9%
Tags
conferences
News

Teva Announces Approval of a Generic Version of Forteo® (teriparatide injection), in the U.S.

Rhea-AI Summary
Teva Pharmaceuticals Inc. (TEVA) receives approval for a generic version of Forteo® (teriparatide injection) to treat osteoporosis in the US, showcasing their strengths in complex generic formulations development and device engineering. The market availability of the product is expected in the coming weeks. The approval aims to enhance access to a critical treatment option for patients, aligning with Teva's strategic goal of sustaining a generic powerhouse.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.31%
Tags
none
-
News

Teva and Royalty Pharma Collaborate to Further Accelerate Olanzapine LAI Program

Rhea-AI Summary
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) collaborates with Royalty Pharma plc (Nasdaq: RPRX) to accelerate the clinical research program for olanzapine LAI (TEV-‘749) by receiving up to $125 million in funding. Olanzapine LAI is a long-acting subcutaneous injectable olanzapine for schizophrenia currently in Phase 3. The collaboration aims to support the development of this potential first long-acting olanzapine with a favorable safety profile.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.61%
Tags
none
-
News

Teva Reports Third Quarter 2023 Financial Results and Increases Revenue Guidance

Rhea-AI Summary
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) reported Q3 2023 revenues of $3.9 billion, reflecting a 7% increase from Q3 2022, with a revised 2023 outlook of $15.1 - $15.5 billion. Strong performance of AUSTEDO®, AJOVY®, and the global generics business drove revenue growth. Non-GAAP diluted EPS was $0.60, with cash flow generated from operating activities of $5 million and free cash flow of $229 million. Exclusive collaboration with Sanofi on Anti TL1-A (TEV-‘574) and accelerated Phase 3 results for Olanzapine LAI (TEV-‘749) were highlighted. Teva api's new CEO and management team were announced.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.22%
Tags
earnings
News

Teva appoints new CEO for Teva api, its Active Pharmaceutical Ingredients Business

Rhea-AI Summary
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) appoints Dr. R. Ananthanarayanan as CEO of Teva Active Pharmaceutical Ingredients business, signaling a pivotal time for the company's strategy and growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.22%
Tags
management

FAQ

What is the current stock price of Teva Pharmaceutical Industries American Depositary Shares (TEVA)?

The current stock price of Teva Pharmaceutical Industries American Depositary Shares (TEVA) is $22.09 as of December 20, 2024.

What is the market cap of Teva Pharmaceutical Industries American Depositary Shares (TEVA)?

The market cap of Teva Pharmaceutical Industries American Depositary Shares (TEVA) is approximately 24.7B.

What does Teva Pharmaceutical Industries Limited specialize in?

Teva specializes in generic drugs, active pharmaceutical ingredients, and proprietary pharmaceuticals.

Where is Teva headquartered?

Teva is headquartered in Tel Aviv, Israel.

What are some of Teva's key products?

Key products include Copaxone, Ajovy, Austedo, Qvar, ProAir, Truxima, Herzuma, and Bendeka/Treanda.

In which regions does Teva operate?

Teva operates in North America, Europe, Japan, Russia, and Israel.

How much of Teva's sales come from North America?

Approximately 50% of Teva's sales come from North America.

What therapeutic areas does Teva focus on?

Teva focuses on central nervous system, respiratory, and oncology therapeutic areas.

What is Anda?

Anda is a U.S.-based distributor of generic and specialty drugs owned by Teva.

Does Teva offer contract manufacturing services?

Yes, Teva offers contract manufacturing services.

What role does Teva play in the U.S. generic prescription market?

Teva accounts for a high-single-digit percentage of the total number of generic prescriptions in the U.S.

What recent advancements has Teva made?

Teva has made advancements in biosimilars and innovative treatments across its therapeutic areas.

Stock TEVA logo
Teva Pharmaceutical Industries Limited American Depositary Shares

NYSE:TEVA

TEVA Rankings

#458 Ranked by Market Cap
N/A Ranked by Dividends

TEVA Stock Data

24.72B
1.13B
0%
57.83%
1.87%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
TEL AVIV